Legend Biotech and Janssen’s investigational CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) has been given breakthrough therapy designation in China as a potential treatment of relapsed or refractory multiple myeloma. Cilta-cel refers to both LCAR-B38M, the name given to the therapy in China, and JNJ-4528, the name by which it is known outside of China. The decision by the Chinese Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) is meant to accelerate…
You must be logged in to read/download the full post.
The post Cilta-cel, CAR T-cell Treatment, Named Breakthrough Therapy in China appeared first on BioNewsFeeds.